ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Atopic Dermatitis
Dermatitis
Pruritus
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity

Eczema trials near Cincinnati, OH, USA:

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema...

Enrolling
Atopic Dermatitis (Eczema)
Drug: ARQ-151 cream 0.05%

Phase 2

Arcutis Biotherapeutics
Arcutis Biotherapeutics

Mason, Ohio, United States and 12 other locations

This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S...

Enrolling
Atopic Dermatitis
Drug: Fluocinonide Ointment
Drug: Hydrocortisone Ointment

Phase 1, Phase 2

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Cincinnati, Ohio, United States and 7 other locations

Locations recently updated

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Enrolling
Atopic Dermatitis
Biological: Barzolvolimab
Drug: Matching placebo

Phase 2

Celldex Therapeutics
Celldex Therapeutics

Cincinnati, Ohio, United States and 40 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Cincinnati, Ohio, United States and 555 other locations

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderat...

Enrolling
Atopic Dermatitis
Drug: APG777

Phase 2

Apogee Therapeutics, Inc.

Mason, Ohio, United States and 31 other locations

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Active, not recruiting
Moderate-to-Severe Atopic Dermatitis
Drug: Nemolizumab

Phase 3

Galderma
Galderma

Cincinnati, Ohio, United States and 342 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems